NEW YORK (GenomeWeb News) – Rosetta Genomics reported after the close of the market Tuesday that its second-quarter net loss rose 62 percent, as well as plans to eventually spin off its new cleantech division.

The Rehovot, Israel-based developer of microRNA-based tests brought in revenues of $14,000 for the three-month period ended June 30, compared to no revenues for the second quarter of 2008. Rosetta noted that revenues it previously reported for Parkway Clinical Laboratories, which it sold for $2.5 million during the quarter, is now recorded under discontinued operations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.